Anxo Pharmaceutical announced yesterday the transfer of five commercialized drug licenses to Synmosa. This marks the fourth collaboration between the two firms, highlighting Anxo Pharmaceutical’s strategy of asset revitalization.

• Portfolio Details: The transferred assets include three anti-diabetic medications, one antibiotic, and one treatment for mild-to-moderate Alzheimer’s and Parkinson’s disease. Revenue from these transfers will be recognized as milestones are achieved.
• Financial Performance: Anxo Pharmaceutical reported January revenue of NT$91.59 million (+33.13% YoY), driven by strong demand for Central Nervous System (CNS) and cardiovascular drugs due to recent cold surges.
• R&D and Global Expansion: GM Yen Lin-chuang emphasized the company’s leadership in Difficult Generics and Drug Delivery Systems (DDS). In 2025, the company obtained 11 drug licenses (6 of which were first-to-market generics). Its proprietary CNS drug, AX251 (for schizophrenia), has received U.S. FDA clearance to begin Phase I trials. The company has also completed licensing deals in Indonesia, the Philippines, Thailand, South Korea, and the Middle East.

Resource: 瑩碩五張藥證轉讓健喬 可收取簽約金及里程碑金